Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABNCoV2 cVLP based COVID-2019 vaccine - AdaptVac

Drug Profile

ABNCoV2 cVLP based COVID-2019 vaccine - AdaptVac

Alternative Names: ABNCoV2; ABNCoV2 Vaccine; ABNCoV2-cVLP based COVID-19 vaccine; Coronavirus vaccine - AdaptVac; COVID-19 cVLP vaccine - AdaptVac; COVID-19 vaccine - AdaptVac; cVLP-RBD; RBDn-CLP

Latest Information Update: 23 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AdaptVac
  • Developer AdaptVac; Bavarian Nordic
  • Class COVID-19 vaccines; Subunit vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections

Most Recent Events

  • 23 Jan 2023 Bavarian Nordic completes phase-II trial in COVID-2019 infections (Prevention) in Germany (IM) (NCT05077267) (EudraCT2021-001393-31) (AdaptVac pipeline; January 2023)
  • 19 Oct 2022 AdaptVac complete enrolment in its phase II trial in Covid-2019 infections in Germany
  • 17 Oct 2022 Updated immunogenicity data from a phase II trial in Covid-2019 infections released by Bavarian Nordic
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top